{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:41:07Z","timestamp":1792431667289,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant immunochemotherapy is increasingly used for resectable locally advanced gastric cancer (LAGC) and gastroesophageal junction (EGJ) adenocarcinoma, yet the optimal chemotherapy backbone for PD-1 blockade remains unclear. We compared neoadjuvant PD-1 inhibitor plus S-1+oxaliplatin (SOX) versus PD-1 inhibitor plus 5-FU+oxaliplatin+Docetaxel+Leucovorin (FLOT) in a real-world cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective study included patients with resectable, HER2-negative LAGC\/EGJ adenocarcinoma (cT3\u20134b, any N+, M0; ECOG 0\u20131) treated between July 2020 and July 2025. Patients received neoadjuvant PD-1 inhibitor plus SOX or PD-1 inhibitor plus FLOT (3\u20135 cycles) followed by D2 gastrectomy. The primary endpoint was pathological complete response (pCR). Secondary endpoints included major pathological response (MPR), radiologic response (RECIST v1.1), perioperative outcomes, treatment-related adverse events (CTCAE v5.0), recurrence-free survival (RFS), and overall survival (OS). Survival was analyzed using Kaplan\u2013Meier methods and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 247 patients were enrolled (PD-1+SOX, n=141; PD-1+FLOT, n=106) with comparable baseline characteristics. Radiologic outcomes were similar between groups (ORR: 70.92% vs 66.98%, p=0.507; DCR: 87.23% vs 85.85%, p=0.752). Pathological responses did not differ significantly (pCR: 20.57% vs 16.98%, p=0.477; MPR: 37.59% vs 31.13%, p=0.292). Any-grade treatment-related adverse events occurred in 67.38% and 75.47% of patients, and grade \u22653 events in 19.15% and 26.42%, respectively; no treatment-related deaths occurred. R0 resection rates were high (100% vs 99.06%). Operative time and estimated blood loss were higher in the PD-1+FLOT group (p=0.010 and p=0.040), while postoperative complication rates were comparable. With median follow-up of 21 months (12\u201352) and 20 months (10\u201346), there were no significant differences in OS (HR 1.155, 95% CI 0.624\u20132.138) or RFS (HR 0.805, 95% CI 0.461\u20131.405). In multivariable analyses, non-MPR was an independent risk factor for both OS and RFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Neoadjuvant PD-1 inhibitor plus SOX and plus FLOT yielded comparable response rates, survival outcomes, and safety profiles in patients with resectable LAGC\/EGJ adenocarcinoma. PD-1+SOX was associated with less operative burden, and MPR remained independently associated with OS and RFS, supporting its value for risk stratification and treatment optimization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1782029","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:04:21Z","timestamp":1772003061000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Neoadjuvant PD-1 inhibitor combined with FLOT versus SOX for locally advanced gastric cancer: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhenshun","family":"Li","sequence":"first","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Second Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]},{"name":"Department of Radiology, 920th Hospital of Joint Logistics Support Force, PLA","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanli","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"Ca-Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"CD008107","DOI":"10.1002\/14651858.CD008107","article-title":"Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus","volume":"2013","author":"Ronellenfitsch","year":"2013","journal-title":"Cochrane Db Syst Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30531-9","article-title":"Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial","volume":"17","author":"Al-Batran","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2015","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000130","article-title":"Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)","volume":"2","author":"Satake","year":"2017","journal-title":"Esmo Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.033","article-title":"Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: A randomized phase III trial (RESOLVE trial)","volume":"30","author":"Ji","year":"2019","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6093","DOI":"10.1038\/s41467-020-19965-6","article-title":"Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer","volume":"11","author":"Sah","year":"2020","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103494","article-title":"Neoadjuvant FLOT versus SOX chemotherapy in locally advanced gastric cancer: secondary outcomes of a single-centre, open-label, randomised, exploratory phase 2 trial","volume":"88","author":"Sah","year":"2025","journal-title":"Eclinicalmedicine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.075","article-title":"Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study","volume":"34","author":"Shitara","year":"2023","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03982-4","article-title":"Dose-finding study of modified FLOT (mFLOT) regimen as first-line treatment in Chinese patients with metastatic adenocarcinoma of stomach","volume":"85","author":"Zhou","year":"2020","journal-title":"Cancer Chemoth Pharm"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-024-01536-7","article-title":"Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II\/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial","volume":"17","author":"Wang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastrooesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"New Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13728-5","article-title":"Is pathologic complete response a good predictor for the long-term, clinical outcome in patients with gastric cancer after neoadjuvant chemotherapy? A retrospective, multi-institution study in China","volume":"30","author":"Lin","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41746-025-02236-3","article-title":"Deep multimodal state-space fusion of endoscopic-radiomic and clinical data for survival prediction in colorectal cancer","volume":"8","author":"Wang","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mdr2.70038","article-title":"Single-cell transcriptomic analysis reveals epithelial-mesenchymal transition and key gene AGRN as a universal programme in gastrointestinal tumours by an artificial intelligence-derived prognostic index","author":"Ni","year":"2025","journal-title":"Med Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41746-025-02287-6","article-title":"Geometric multi-instance learning for weakly supervised gastric cancer segmentation","volume":"9","author":"Huang","year":"2026","journal-title":"NPJ Digit Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41587-021-01070-8","article-title":"Improved prediction of immune checkpoint blockade efficacy across multiple cancer types","volume":"40","author":"Chowell","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41392-024-01932-y","article-title":"Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Tar"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1126\/science.aba2609","article-title":"Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade","volume":"372","author":"Berry","year":"2021","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1782029\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:04:22Z","timestamp":1772003062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1782029\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2026.1782029"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1782029","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"1782029"}}